Sirios Capital Management L P Has $11.87 Million Holdings in Eli Lilly and Company (NYSE:LLY)

Sirios Capital Management L P lessened its stake in Eli Lilly and Company (NYSE:LLY - Free Report) by 2.9% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 15,375 shares of the company's stock after selling 465 shares during the quarter. Eli Lilly and Company accounts for about 2.1% of Sirios Capital Management L P's portfolio, making the stock its 16th largest holding. Sirios Capital Management L P's holdings in Eli Lilly and Company were worth $11,870,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Highline Wealth Partners LLC lifted its holdings in Eli Lilly and Company by 80.0% in the fourth quarter. Highline Wealth Partners LLC now owns 45 shares of the company's stock valued at $35,000 after acquiring an additional 20 shares during the last quarter. FPC Investment Advisory Inc. lifted its position in Eli Lilly and Company by 358.3% in the fourth quarter. FPC Investment Advisory Inc. now owns 55 shares of the company's stock valued at $45,000 after buying an additional 43 shares during the last quarter. Prudent Man Investment Management Inc. purchased a new position in Eli Lilly and Company during the fourth quarter worth about $48,000. Compass Financial Services Inc acquired a new stake in shares of Eli Lilly and Company during the fourth quarter valued at about $50,000. Finally, Fiduciary Advisors Inc. purchased a new stake in shares of Eli Lilly and Company in the 4th quarter valued at approximately $58,000. Hedge funds and other institutional investors own 82.53% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms have weighed in on LLY. Leerink Partners set a $950.00 target price on Eli Lilly and Company in a research report on Friday, January 17th. The Goldman Sachs Group raised shares of Eli Lilly and Company from a "neutral" rating to a "buy" rating and decreased their price target for the company from $892.00 to $888.00 in a research report on Tuesday, April 8th. Guggenheim cut their price objective on Eli Lilly and Company from $973.00 to $928.00 and set a "buy" rating on the stock in a research report on Monday, April 14th. Cantor Fitzgerald started coverage on Eli Lilly and Company in a report on Tuesday. They issued an "overweight" rating and a $975.00 target price for the company. Finally, Truist Financial upped their price target on Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the stock a "buy" rating in a report on Monday, February 3rd. Two investment analysts have rated the stock with a hold rating and eighteen have given a buy rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $1,017.00.

Insider Buying and Selling at Eli Lilly and Company

In related news, CAO Donald A. Zakrowski sold 1,000 shares of Eli Lilly and Company stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $818.24, for a total transaction of $818,240.00. Following the transaction, the chief accounting officer now directly owns 5,840 shares of the company's stock, valued at $4,778,521.60. The trade was a 14.62 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.13% of the stock is currently owned by company insiders.

Eli Lilly and Company Stock Up 3.8 %

Shares of Eli Lilly and Company stock opened at $861.11 on Friday. The company has a debt-to-equity ratio of 2.00, a current ratio of 1.15 and a quick ratio of 0.97. The company has a market capitalization of $816.48 billion, a PE ratio of 73.54, a P/E/G ratio of 1.40 and a beta of 0.51. Eli Lilly and Company has a 1-year low of $677.09 and a 1-year high of $972.53. The business has a 50-day moving average of $827.14 and a 200-day moving average of $818.81.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its earnings results on Thursday, February 6th. The company reported $5.32 EPS for the quarter, missing analysts' consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. As a group, equities analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.